KIAA1614: A Potential Drug Target for Neurological Disorders (G57710)

Target Name: KIAA1614

NCBI ID: G57710

KIAA1614

Other Name(s): RP11-46A10.3 | K1614_HUMAN | Uncharacterized protein KIAA1614

KIAA1614: A Potential Drug Target for Neurological Disorders

KIAA1614 (RP11-46A10.3) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a member of the KIAA family of proteins, which are involved in the intracellular signaling pathway known as the K+ channel regulation.

KIAA1614 is known for its role in regulating the activity of the neurotransmitter acetylcholine, which is involved in the development and maintenance of memories and learning. In addition, KIAA1614 has also been shown to play a role in the regulation of ion channels, including the sodium (Na+) and potassium (K+) channels.

The research on KIAA1614 has led to the hypothesis that it may be a drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. This is because the disruption of KIAA1614 has been observed to be associated with the development of these disorders, and its inhibition has been shown to improve the symptoms in animal models of these conditions.

In addition to its potential therapeutic applications, KIAA1614 has also been shown to be a potential biomarker for these disorders. The levels of KIAA1614 have been found to be decreased in the brains of individuals with Alzheimer's disease and other neurological disorders. Furthermore, studies have shown that KIAA1614 is downregulated in the blood vessels of individuals with depression, and its levels are associated with the development of these conditions.

The precise mechanism by which KIAA1614 is involved in the regulation of neurotransmitters and ion channels is not yet fully understood. However, it is known that KIAA1614 plays a role in the regulation of the activity of the neurotransmitter acetylcholine, which is involved in the development and maintenance of memories and learning.

In addition, KIAA1614 has also been shown to play a role in the regulation of ion channels, including the sodium (Na+) and potassium (K+) channels. The disruption of KIAA1614 has been observed to be associated with the development of certain ion channels, including the sodium channels that are involved in the regulation of muscle and nerve activity.

Overall, the research on KIAA1614 has led to the hypothesis that it may be a drug target or biomarker for various neurological and psychiatric disorders. Its potential therapeutic applications and biomarker potential make it an important area of 鈥嬧?媟esearch for the development of new treatments for these conditions .

Protein Name: KIAA1614

The "KIAA1614 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIAA1614 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets